Meeting Coverage
AASLD: HCV Outcomes Under Scrutiny
Treatment now 'predictably' good in trials but what about real world?
AASLD: HCV Outcomes Under Scrutiny
Treatment now 'predictably' good in trials but what about real world?
by Michael Smith
North American Correspondent, MedPage Today
North American Correspondent, MedPage Today
BOSTON -- With treatment for hepatitis C (HCV) reaching a peak of efficacy, attention is turning to issues of access and outcomes at the annual meeting of the American Association for the Study of Liver Diseases here.
"There are some new drugs and new combinations of drugs" being reported at the meeting, according to the society's president-elect, Anna Lok, MD, of the University of Michigan Health System in Ann Arbor.
She said investigators are now beginning to ask -- and report on -- the real-world effects of the tsunami of new direct-acting agents against HCV that has dominated the liver meeting for the past few years.
Continue reading....
MedPage Today - Meeting Coverage
AASLD: Focus on Liver Broadens
Fatty liver disease expected to get lion's share of spotlight
"There are some new drugs and new combinations of drugs" being reported at the meeting, according to the society's president-elect, Anna Lok, MD, of the University of Michigan Health System in Ann Arbor.
She said investigators are now beginning to ask -- and report on -- the real-world effects of the tsunami of new direct-acting agents against HCV that has dominated the liver meeting for the past few years.
Continue reading....
MedPage Today - Meeting Coverage
AASLD: Focus on Liver Broadens
Fatty liver disease expected to get lion's share of spotlight
by Michael Smith
North American Correspondent, MedPage Today
BOSTON -- This year's edition of the Liver Meeting -- the annual meeting of the American Association for the Study of Liver Diseases -- will have a broader focus than in recent years, an organizer said.
North American Correspondent, MedPage Today
BOSTON -- This year's edition of the Liver Meeting -- the annual meeting of the American Association for the Study of Liver Diseases -- will have a broader focus than in recent years, an organizer said.
No comments:
Post a Comment